 Matthew Rossman
Concepts (272)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vasodilation | 22 | 2025 | 499 | 3.570 |
Why?
| | Endothelium, Vascular | 19 | 2025 | 927 | 3.330 |
Why?
| | Aging | 21 | 2025 | 1864 | 2.630 |
Why?
| | Exercise | 24 | 2025 | 2057 | 2.580 |
Why?
| | Brachial Artery | 9 | 2025 | 205 | 2.440 |
Why?
| | Vascular Stiffness | 12 | 2025 | 494 | 2.260 |
Why?
| | Leg | 16 | 2025 | 236 | 2.230 |
Why?
| | Antioxidants | 6 | 2023 | 584 | 2.090 |
Why?
| | Oxidative Stress | 14 | 2025 | 1317 | 1.740 |
Why?
| | Nitric Oxide | 14 | 2023 | 915 | 1.620 |
Why?
| | Mitochondria | 6 | 2025 | 948 | 1.600 |
Why?
| | Vascular Diseases | 5 | 2023 | 243 | 1.260 |
Why?
| | Muscle Fatigue | 5 | 2017 | 102 | 1.260 |
Why?
| | Blood Vessels | 3 | 2020 | 187 | 1.150 |
Why?
| | Pulmonary Ventilation | 2 | 2022 | 79 | 1.140 |
Why?
| | Cellular Senescence | 5 | 2025 | 189 | 1.130 |
Why?
| | Muscle, Skeletal | 17 | 2025 | 1724 | 1.050 |
Why?
| | Femoral Artery | 10 | 2025 | 179 | 1.040 |
Why?
| | Postmenopause | 2 | 2025 | 366 | 0.990 |
Why?
| | Reactive Oxygen Species | 11 | 2025 | 622 | 0.980 |
Why?
| | Regional Blood Flow | 15 | 2025 | 474 | 0.980 |
Why?
| | Endothelial Cells | 8 | 2025 | 785 | 0.950 |
Why?
| | Movement | 8 | 2022 | 278 | 0.900 |
Why?
| | Ascorbic Acid | 3 | 2021 | 177 | 0.900 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 5 | 2017 | 1040 | 0.880 |
Why?
| | NAD | 1 | 2023 | 77 | 0.810 |
Why?
| | Exercise Tolerance | 6 | 2025 | 279 | 0.770 |
Why?
| | Citrulline | 1 | 2022 | 45 | 0.740 |
Why?
| | Quadriceps Muscle | 7 | 2021 | 133 | 0.730 |
Why?
| | Healthy Lifestyle | 2 | 2018 | 34 | 0.720 |
Why?
| | Dietary Supplements | 6 | 2025 | 561 | 0.710 |
Why?
| | Kidney Diseases | 1 | 2025 | 408 | 0.710 |
Why?
| | Aged | 35 | 2025 | 23961 | 0.710 |
Why?
| | Sodium Nitrite | 1 | 2021 | 39 | 0.690 |
Why?
| | Cardiovascular Diseases | 7 | 2025 | 2111 | 0.680 |
Why?
| | Bronchi | 1 | 2022 | 260 | 0.660 |
Why?
| | Physical Endurance | 3 | 2025 | 275 | 0.650 |
Why?
| | Stroke Volume | 4 | 2019 | 612 | 0.610 |
Why?
| | Anti-Asthmatic Agents | 1 | 2022 | 395 | 0.560 |
Why?
| | Mitochondria, Muscle | 5 | 2021 | 116 | 0.550 |
Why?
| | Heating | 1 | 2017 | 23 | 0.550 |
Why?
| | Kidney | 1 | 2025 | 1468 | 0.540 |
Why?
| | Muscle Contraction | 7 | 2021 | 424 | 0.500 |
Why?
| | Humans | 65 | 2025 | 137585 | 0.490 |
Why?
| | Pulse Wave Analysis | 7 | 2025 | 272 | 0.490 |
Why?
| | Male | 47 | 2025 | 67762 | 0.460 |
Why?
| | Asthma | 2 | 2022 | 2295 | 0.460 |
Why?
| | Fatigue | 2 | 2014 | 329 | 0.460 |
Why?
| | Young Adult | 23 | 2025 | 13209 | 0.460 |
Why?
| | Sympathetic Nervous System | 4 | 2025 | 182 | 0.450 |
Why?
| | Flavonols | 2 | 2025 | 18 | 0.450 |
Why?
| | Middle Aged | 22 | 2025 | 33479 | 0.450 |
Why?
| | Arteries | 5 | 2024 | 269 | 0.450 |
Why?
| | Hyperemia | 5 | 2022 | 49 | 0.440 |
Why?
| | Heart | 1 | 2018 | 655 | 0.430 |
Why?
| | Vasoconstriction | 6 | 2022 | 202 | 0.430 |
Why?
| | Thioctic Acid | 1 | 2013 | 11 | 0.420 |
Why?
| | Vitamin E | 1 | 2013 | 124 | 0.400 |
Why?
| | Nitrates | 3 | 2022 | 92 | 0.400 |
Why?
| | Female | 31 | 2025 | 73304 | 0.390 |
Why?
| | Smoking Water Pipes | 2 | 2023 | 9 | 0.390 |
Why?
| | Water Pipe Smoking | 2 | 2023 | 9 | 0.390 |
Why?
| | Knee | 1 | 2012 | 68 | 0.370 |
Why?
| | Oxygen Consumption | 8 | 2025 | 696 | 0.370 |
Why?
| | Age Factors | 6 | 2025 | 3295 | 0.350 |
Why?
| | Adult | 25 | 2025 | 37929 | 0.350 |
Why?
| | Blood Flow Velocity | 6 | 2019 | 413 | 0.350 |
Why?
| | Resistance Training | 2 | 2023 | 164 | 0.340 |
Why?
| | Diet, Western | 2 | 2021 | 81 | 0.340 |
Why?
| | Cross-Over Studies | 3 | 2023 | 564 | 0.340 |
Why?
| | Aorta | 5 | 2025 | 417 | 0.340 |
Why?
| | Healthy Volunteers | 4 | 2021 | 199 | 0.340 |
Why?
| | Hand Strength | 4 | 2025 | 123 | 0.320 |
Why?
| | Exercise Test | 3 | 2022 | 625 | 0.320 |
Why?
| | Blood Pressure | 7 | 2023 | 1786 | 0.300 |
Why?
| | Posture | 5 | 2016 | 185 | 0.300 |
Why?
| | Electromyography | 4 | 2014 | 400 | 0.290 |
Why?
| | Caloric Restriction | 2 | 2020 | 124 | 0.280 |
Why?
| | Atherosclerosis | 3 | 2018 | 415 | 0.270 |
Why?
| | Inflammation | 6 | 2024 | 2837 | 0.270 |
Why?
| | Physical Conditioning, Animal | 2 | 2021 | 257 | 0.260 |
Why?
| | Biomarkers | 4 | 2025 | 4149 | 0.250 |
Why?
| | Respiratory Function Tests | 2 | 2022 | 600 | 0.250 |
Why?
| | Motor Activity | 4 | 2024 | 718 | 0.240 |
Why?
| | Mice, Inbred C57BL | 7 | 2025 | 5757 | 0.240 |
Why?
| | Feedback, Physiological | 3 | 2014 | 77 | 0.240 |
Why?
| | Animals | 16 | 2025 | 36940 | 0.230 |
Why?
| | Respiratory Muscles | 2 | 2023 | 33 | 0.230 |
Why?
| | Flavonoids | 1 | 2025 | 85 | 0.230 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2025 | 127 | 0.230 |
Why?
| | Premenopause | 1 | 2025 | 131 | 0.220 |
Why?
| | Case-Control Studies | 5 | 2025 | 3556 | 0.220 |
Why?
| | Spermidine | 1 | 2024 | 19 | 0.210 |
Why?
| | Repetitive Sequences, Nucleic Acid | 1 | 2024 | 113 | 0.210 |
Why?
| | Mice | 12 | 2025 | 17787 | 0.210 |
Why?
| | Nicotinamide Mononucleotide | 1 | 2023 | 9 | 0.210 |
Why?
| | Arterial Pressure | 5 | 2019 | 126 | 0.210 |
Why?
| | Doxorubicin | 1 | 2025 | 362 | 0.210 |
Why?
| | Lipoproteins, LDL | 1 | 2023 | 116 | 0.200 |
Why?
| | Endothelin-1 | 2 | 2016 | 182 | 0.200 |
Why?
| | Acetylcholine | 2 | 2023 | 185 | 0.200 |
Why?
| | Vaping | 1 | 2023 | 60 | 0.200 |
Why?
| | Inflammation Mediators | 1 | 2025 | 513 | 0.190 |
Why?
| | Adolescent | 7 | 2023 | 21513 | 0.190 |
Why?
| | Electronic Nicotine Delivery Systems | 1 | 2023 | 103 | 0.190 |
Why?
| | Social Class | 1 | 2024 | 282 | 0.190 |
Why?
| | Administration, Oral | 2 | 2015 | 816 | 0.190 |
Why?
| | Treatment Outcome | 4 | 2022 | 10811 | 0.180 |
Why?
| | Spirostans | 1 | 2021 | 4 | 0.180 |
Why?
| | Breathing Exercises | 1 | 2021 | 21 | 0.180 |
Why?
| | Glomerular Filtration Rate | 1 | 2025 | 746 | 0.180 |
Why?
| | Inhalation | 1 | 2021 | 29 | 0.180 |
Why?
| | Hypertension | 2 | 2021 | 1295 | 0.180 |
Why?
| | Cardiovascular System | 3 | 2020 | 137 | 0.170 |
Why?
| | Hypotension | 1 | 2022 | 122 | 0.170 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2021 | 107 | 0.170 |
Why?
| | Double-Blind Method | 3 | 2023 | 1993 | 0.170 |
Why?
| | Cardiovascular Abnormalities | 1 | 2019 | 13 | 0.160 |
Why?
| | Pressoreceptors | 1 | 2019 | 19 | 0.160 |
Why?
| | Cells, Cultured | 2 | 2025 | 4193 | 0.160 |
Why?
| | Dementia | 1 | 2023 | 259 | 0.160 |
Why?
| | Glucose Intolerance | 1 | 2021 | 146 | 0.160 |
Why?
| | Drug Monitoring | 1 | 2021 | 218 | 0.160 |
Why?
| | Supine Position | 2 | 2016 | 39 | 0.150 |
Why?
| | Sex Factors | 1 | 2025 | 2071 | 0.150 |
Why?
| | Models, Animal | 1 | 2021 | 384 | 0.150 |
Why?
| | DNA Methylation | 1 | 2024 | 643 | 0.150 |
Why?
| | Receptors, Adrenergic, beta-1 | 1 | 2019 | 46 | 0.150 |
Why?
| | Coronary Circulation | 1 | 2019 | 143 | 0.150 |
Why?
| | Electron Transport | 1 | 2018 | 115 | 0.150 |
Why?
| | Peptides, Cyclic | 3 | 2016 | 259 | 0.150 |
Why?
| | Athletes | 1 | 2022 | 423 | 0.150 |
Why?
| | Hemodynamics | 6 | 2023 | 1113 | 0.150 |
Why?
| | Fasting | 1 | 2020 | 281 | 0.140 |
Why?
| | Energy Metabolism | 2 | 2021 | 922 | 0.140 |
Why?
| | Oncogene Protein p21(ras) | 1 | 2017 | 16 | 0.140 |
Why?
| | Endothelin Receptor Antagonists | 2 | 2016 | 62 | 0.140 |
Why?
| | Heart Rate | 6 | 2023 | 822 | 0.140 |
Why?
| | Habits | 1 | 2017 | 49 | 0.140 |
Why?
| | Coronary Vessels | 1 | 2019 | 248 | 0.130 |
Why?
| | Muscle Fibers, Skeletal | 1 | 2018 | 218 | 0.130 |
Why?
| | Bicycling | 2 | 2021 | 114 | 0.130 |
Why?
| | Congresses as Topic | 1 | 2018 | 233 | 0.130 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2023 | 617 | 0.130 |
Why?
| | Primary Prevention | 1 | 2018 | 196 | 0.120 |
Why?
| | Cardiac Catheterization | 1 | 2019 | 530 | 0.120 |
Why?
| | Cardiovascular Physiological Phenomena | 1 | 2015 | 42 | 0.120 |
Why?
| | Ventricular Function, Left | 1 | 2019 | 534 | 0.120 |
Why?
| | Metabolomics | 1 | 2021 | 678 | 0.120 |
Why?
| | Reflex | 1 | 2015 | 68 | 0.120 |
Why?
| | Reproducibility of Results | 3 | 2022 | 3284 | 0.120 |
Why?
| | Autonomic Nervous System | 1 | 2015 | 75 | 0.120 |
Why?
| | Life Style | 1 | 2017 | 490 | 0.110 |
Why?
| | Cell Respiration | 3 | 2021 | 103 | 0.110 |
Why?
| | Maximal Midexpiratory Flow Rate | 1 | 2014 | 3 | 0.110 |
Why?
| | Peak Expiratory Flow Rate | 1 | 2014 | 37 | 0.110 |
Why?
| | Muscle Strength | 3 | 2023 | 317 | 0.110 |
Why?
| | Pyramidal Tracts | 1 | 2014 | 31 | 0.110 |
Why?
| | omega-N-Methylarginine | 4 | 2015 | 27 | 0.110 |
Why?
| | Bronchoconstriction | 1 | 2014 | 32 | 0.110 |
Why?
| | Adrenergic beta-2 Receptor Agonists | 1 | 2014 | 37 | 0.110 |
Why?
| | Ultrasonography, Doppler | 4 | 2016 | 124 | 0.110 |
Why?
| | Receptors, Opioid, mu | 1 | 2014 | 74 | 0.110 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2017 | 382 | 0.110 |
Why?
| | Shear Strength | 1 | 2014 | 67 | 0.110 |
Why?
| | Extremities | 1 | 2014 | 131 | 0.100 |
Why?
| | Cardiac Output | 4 | 2015 | 165 | 0.100 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2017 | 528 | 0.100 |
Why?
| | Vital Capacity | 1 | 2014 | 311 | 0.100 |
Why?
| | Electron Spin Resonance Spectroscopy | 1 | 2013 | 95 | 0.100 |
Why?
| | Muscle, Smooth, Vascular | 1 | 2016 | 446 | 0.100 |
Why?
| | Free Radicals | 1 | 2013 | 110 | 0.100 |
Why?
| | Recovery of Function | 1 | 2017 | 653 | 0.100 |
Why?
| | Forced Expiratory Volume | 1 | 2014 | 531 | 0.100 |
Why?
| | Coronary Artery Disease | 1 | 2019 | 698 | 0.100 |
Why?
| | Single-Blind Method | 1 | 2013 | 282 | 0.100 |
Why?
| | Bronchodilator Agents | 1 | 2014 | 252 | 0.100 |
Why?
| | Fentanyl | 3 | 2021 | 94 | 0.100 |
Why?
| | Drug Combinations | 1 | 2013 | 343 | 0.090 |
Why?
| | Central Nervous System | 1 | 2014 | 258 | 0.090 |
Why?
| | Aged, 80 and over | 1 | 2023 | 7635 | 0.090 |
Why?
| | Drug Administration Schedule | 1 | 2013 | 786 | 0.090 |
Why?
| | Carotid Arteries | 2 | 2024 | 206 | 0.090 |
Why?
| | Motor Neurons | 1 | 2013 | 234 | 0.090 |
Why?
| | Spinal Cord | 1 | 2013 | 370 | 0.080 |
Why?
| | Knee Joint | 1 | 2014 | 409 | 0.080 |
Why?
| | Sepsis | 1 | 2016 | 617 | 0.080 |
Why?
| | Follow-Up Studies | 1 | 2018 | 5131 | 0.070 |
Why?
| | Biological Availability | 2 | 2021 | 148 | 0.070 |
Why?
| | Heart Failure | 1 | 2019 | 2236 | 0.060 |
Why?
| | Popliteal Artery | 1 | 2025 | 59 | 0.060 |
Why?
| | Photoplethysmography | 2 | 2016 | 18 | 0.060 |
Why?
| | Aniline Compounds | 1 | 2025 | 102 | 0.060 |
Why?
| | Fingers | 2 | 2016 | 88 | 0.050 |
Why?
| | Infusions, Intra-Arterial | 2 | 2015 | 59 | 0.050 |
Why?
| | Respiratory Therapy | 1 | 2023 | 23 | 0.050 |
Why?
| | Elastic Modulus | 1 | 2024 | 123 | 0.050 |
Why?
| | Nitric Oxide Synthase | 2 | 2015 | 240 | 0.050 |
Why?
| | Nitric Oxide Synthase Type III | 2 | 2016 | 204 | 0.050 |
Why?
| | Time Factors | 3 | 2021 | 6828 | 0.050 |
Why?
| | Forearm | 1 | 2023 | 119 | 0.050 |
Why?
| | Lower Extremity | 2 | 2019 | 427 | 0.050 |
Why?
| | Hypercapnia | 1 | 2023 | 53 | 0.050 |
Why?
| | Muscles | 1 | 2023 | 326 | 0.050 |
Why?
| | Sulfonamides | 1 | 2025 | 513 | 0.050 |
Why?
| | Injections, Spinal | 1 | 2021 | 105 | 0.040 |
Why?
| | Carbon Dioxide | 1 | 2023 | 267 | 0.040 |
Why?
| | Blood Circulation | 1 | 2021 | 41 | 0.040 |
Why?
| | Neurons, Afferent | 1 | 2021 | 97 | 0.040 |
Why?
| | Nicotine | 1 | 2023 | 334 | 0.040 |
Why?
| | Random Allocation | 1 | 2021 | 353 | 0.040 |
Why?
| | Cerebrovascular Circulation | 1 | 2023 | 243 | 0.040 |
Why?
| | Mouth | 1 | 2021 | 87 | 0.040 |
Why?
| | Analgesics, Opioid | 2 | 2021 | 1000 | 0.040 |
Why?
| | Social Determinants of Health | 1 | 2024 | 267 | 0.040 |
Why?
| | Enzyme Inhibitors | 2 | 2015 | 840 | 0.040 |
Why?
| | Interleukin-6 | 1 | 2024 | 778 | 0.040 |
Why?
| | Infusions, Intralesional | 1 | 2019 | 1 | 0.040 |
Why?
| | Diet, High-Fat | 1 | 2021 | 247 | 0.040 |
Why?
| | Adrenergic Antagonists | 1 | 2019 | 7 | 0.040 |
Why?
| | Epigenesis, Genetic | 1 | 2024 | 660 | 0.040 |
Why?
| | Risk Assessment | 2 | 2019 | 3457 | 0.040 |
Why?
| | Retrospective Studies | 1 | 2016 | 15657 | 0.040 |
Why?
| | Blood Pressure Determination | 1 | 2019 | 157 | 0.040 |
Why?
| | Risk Factors | 2 | 2024 | 10388 | 0.040 |
Why?
| | Immunity, Innate | 1 | 2024 | 828 | 0.040 |
Why?
| | Reference Values | 1 | 2019 | 816 | 0.040 |
Why?
| | Oxygen | 1 | 2022 | 931 | 0.030 |
Why?
| | Oxidative Phosphorylation | 1 | 2018 | 193 | 0.030 |
Why?
| | ROC Curve | 1 | 2019 | 554 | 0.030 |
Why?
| | Homeostasis | 1 | 2021 | 621 | 0.030 |
Why?
| | Energy Intake | 1 | 2020 | 485 | 0.030 |
Why?
| | Adipose Tissue | 1 | 2021 | 635 | 0.030 |
Why?
| | Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 1 | 2016 | 42 | 0.030 |
Why?
| | Electron Transport Complex IV | 1 | 2016 | 60 | 0.030 |
Why?
| | Isocitrate Dehydrogenase | 1 | 2016 | 59 | 0.030 |
Why?
| | Program Development | 1 | 2018 | 364 | 0.030 |
Why?
| | Electron Transport Complex II | 1 | 2015 | 26 | 0.030 |
Why?
| | Electron Transport Complex I | 1 | 2015 | 41 | 0.030 |
Why?
| | Biopsy | 1 | 2018 | 1129 | 0.030 |
Why?
| | Disease Models, Animal | 1 | 2025 | 4295 | 0.030 |
Why?
| | Afferent Pathways | 1 | 2014 | 45 | 0.030 |
Why?
| | Evoked Potentials, Motor | 1 | 2014 | 46 | 0.030 |
Why?
| | Pilot Projects | 1 | 2020 | 1710 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2019 | 2031 | 0.030 |
Why?
| | Electromagnetic Fields | 1 | 2013 | 25 | 0.030 |
Why?
| | Program Evaluation | 1 | 2018 | 898 | 0.030 |
Why?
| | Amino Acids, Branched-Chain | 1 | 2013 | 36 | 0.030 |
Why?
| | Pulmonary Gas Exchange | 1 | 2013 | 121 | 0.030 |
Why?
| | Physical Exertion | 1 | 2014 | 215 | 0.020 |
Why?
| | Endothelin A Receptor Antagonists | 1 | 2012 | 26 | 0.020 |
Why?
| | Microbiota | 1 | 2021 | 762 | 0.020 |
Why?
| | Femoral Vein | 1 | 2012 | 34 | 0.020 |
Why?
| | Receptor, Endothelin A | 1 | 2012 | 65 | 0.020 |
Why?
| | Exercise Therapy | 1 | 2017 | 443 | 0.020 |
Why?
| | Stress, Mechanical | 1 | 2014 | 485 | 0.020 |
Why?
| | Tryptophan | 1 | 2013 | 183 | 0.020 |
Why?
| | Catheterization, Peripheral | 1 | 2012 | 109 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2019 | 2828 | 0.020 |
Why?
| | Vascular Resistance | 1 | 2012 | 375 | 0.020 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2012 | 560 | 0.020 |
Why?
| | Colorado | 1 | 2021 | 4565 | 0.020 |
Why?
| | Lactic Acid | 1 | 2012 | 305 | 0.020 |
Why?
| | Ultrasonography | 1 | 2015 | 759 | 0.020 |
Why?
| | Lipids | 1 | 2014 | 672 | 0.020 |
Why?
| | Prognosis | 1 | 2018 | 4030 | 0.020 |
Why?
| | Cohort Studies | 1 | 2019 | 5742 | 0.020 |
Why?
| | Transcription Factors | 1 | 2016 | 1719 | 0.020 |
Why?
| | Obesity | 1 | 2021 | 2992 | 0.020 |
Why?
| | Prospective Studies | 1 | 2019 | 7604 | 0.020 |
Why?
| | Phenotype | 1 | 2014 | 3196 | 0.010 |
Why?
| | Cross-Sectional Studies | 1 | 2016 | 5472 | 0.010 |
Why?
|
|
Rossman's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|